Efforts toward the realization of Industrial Vision 2035

We held the “FY 2026 Meeting of Compliance Management Officers and Practitioners.”

We have posted a report on our participation in the “16th Annual Conference of the Society for Regulatory Science.”

We have posted the “Results of a Survey of Member Companies of the Drug Evaluation Committee Regarding the Use of the ICF Common Template.”

"Introduction to Patient Preference Research" has been posted.

Three Pharmaceutical Associations from Japan, the U.S., and Europe
Joint Statement on the Proposal to Expand the Cost-Effectiveness Evaluation System

Videos related to the JPMA Code Awareness Month have been posted.

Public and Private Sectors Jointly Highlight the Evolution of the Japanese Market and Clinical Trial Environment at “BIO International Convention 2026”

Regarding the JPMA’s 4th (FY2026) “Call for Proposals for Researcher Support and Grants”

The “FY2026 Guidelines for the Open Call for Researcher Support and Grants” have been published.

We have posted the “Publicly Disclosed Information for FY 2025 Payments” from the “Transparency Guideline for Relationships Between Corporate Activities and Patient Organizations.”

We have posted the “Disclosed Information for Fiscal Year 2025 Payments” under the “Transparency Guideline for the Relation between Corporate Activities and Medical Institutions, etc.”

We have posted a report on our participation in the “ICH Rio de Janeiro Meeting.”

We have posted the report titled “The 19th Survey on Consumer Attitudes Toward Medicines and the Pharmaceutical Industry.”

We have posted a report on the “FY 2026 (53rd) GMP Roundtable.”

We have published the “JPMA Newsletter, July 2026 Issue No. 230.”

We have posted the “Q&A, 5th Edition, Regarding ‘Registration of Clinical Trial Status, etc.’ (Pharmaceutical and Medical Devices Safety and Evaluation Division Notice No. 0831-9, August 31, Reiwa 2).”

We have published an article titled “The Revised Next-Generation Medical Infrastructure Act and Post-Marketing Drug Safety Surveillance: Required Actions for Pharmaceutical Companies.”

Following the Cabinet’s Approval of the “Basic Policy 2026”

We have posted an article titled “JPMA’s Perspective on the FDA Roadmap and Related Matters.”

“Medication Consultation Desk (for Healthcare Professionals)” has been posted.

We have posted “On Institutional Measures to Ensure a Stable Supply of Medicines and Other Products Necessary for Infectious Disease Control and to Promote Antimicrobial Drug Discovery.”

"The Potential for Bioequivalence Evaluation Using Physiological Drug Absorption Models: The Current Status and Future Prospects of Virtual BE" has been published.

Information on the “Symposium on Pediatric Drug Development: ‘Envisioning the Future of Pediatric Drug Development—Challenges in the New Era Brought About by the Revision of the Pharmaceutical and Medical Devices Act,’ to be Held on March 17, 2026” has been posted.

We have posted an article titled “Side Event Report — 79th World Health Assembly (WHA79)”

—Making Drug Discovery and Biotechnology Engines of Japan’s Growth— Following the Publication of the “Working Group Roadmap by the Japan Growth Strategy Council”

Five JPMA Member Companies Participate in “Girls Meet STEM” — Each Company Hosts Its Own Program —

We have posted the “Guide to Creating Terms of Use for the Adverse Reaction Database (DB) Tool.”

Report on Participation in “Medicine Festival 2026—A Science Experience Event for Children and Adults Alike”

Report on the JPMA Media Forum: “The Diverse Value Brought by Innovative Medicines—Using Pediatric Acute Lymphoblastic Leukemia (ALL) as a Case Study”

We have posted the "Survey Report on the Current Status of Application Lags in Japan (March 2026)."

Results of Questionnaire on Patient Public Involvement (PPI/E) Activity Initiatives (conducted February-March 2025)" is now available.

Theory and Practice of Model-based Meta Analysis in Drug Development" is now available.

Top Leaders of Global Biopharmaceutical Companies Meet with Prime Minister Sanae Takaichi

Workshop on April 16, 2026 "What is a Lay Summary that Responds to "I Want to Know"? ~Think Together from the Perspectives of Patients, Regulations, and Practice! ～is now available.

Interview with a Patient Organization: "I wish I had a PAH Association! is changing the future" is now available.

Explanation of "Handling of Provision of Information for Clinical Trials, etc." and Q&A.

Report on "The 45th Public Relations Seminar" is now available.

The 149th Assembly of the Drug Evaluation Committee" is now available.

Presentation materials and video of the symposium "Covariate Adjustment to Improve Statistical Efficiency in Randomized Controlled Trials" are now available

We have published the “JPMA Newsletter, May 2026 Issue No. 229.”

Results of Survey on Clinical Trials Not Relying on Visits to Medical Institutions" is now available.

Digital Applications in Preventive Medicine and Initiatives by Pharmaceutical Companies" is now available.

Explanation Video to Promote Understanding of ICH-E6 (R3)" is now available.

Survey and Discussion on Data Utilization for jRCT and Clinical Trial Notification for ICH M11 Implementation" is now available.

Industry Workshop on the Implementation of the "Clinical Trials Ecosystem Industry Declaration 2025" is now available.

Communication of Drug Information to Create Satisfaction" is now available.

Workshop for Case Evaluation Officers" is now available.

Guidance for Preparation of the "Infectious Disease Evaluation Report" (2026 Edition)" is now available.

Positioning Map Analysis of Patients' Web-based Drug Information Search" is now available.

The "FY2025 Meeting of Compliance Management Managers and Practitioners" was held.

Girls Meet STEM to Experience "The Moment Drugs are Created"-Girls in Junior High and High School Take on the World of Drug Discovery-.

Following the “15th Asia Pharmaceutical Association Cooperation Conference (APAC)”

Materials from the “15th Asia Pharmaceutical Associations Conference (APAC) Press Conference”

A Beginner's Guide to Using NDB in the Pharmaceutical Industry" is now available.

JPMA Newsletter [Extra]: JPMA Holds First Town Hall Meeting! is now available.

Held "2026 Life Science IP Forum

Workshop for Persons Responsible for Product Information Overview Management and Practical Responsibility for Product Information Overview Management in 2025" was held.

The following pages are released / "Names of companies that have adopted the common template for Explanatory and Consent Documents (ICF)" (Japanese only)

Collection of Examples of Cloud System Introduction at Medical Institutions" has been posted on the "Standard Operating Procedures, etc. for Electromagnetic Handling of Clinical Trial Documents (2024 Edition)" page.

Interviews with Patients' Organizations] Patients' Associations are Jewel Boxes! Let's put our thoughts into words! Osaka IBD" is now available.

Analysis of Application Materials for Regenerative Medicine Product Approval (Life Cycle Management Information)" is available.

“Don’t Blindly Believe Medical and Health Information!” Three Organizations Produce and Release Public Awareness Materials for the General Public

Q&A on Commercial Production Digital Transformation (DX) Promotion Task Force (TF) Case Studies" is now available.

Handbook of Regulatory Requirements and Issuances for Electronic Information, Sixth Edition" is now available.

The "Contribution of Clinical Pharmacology to Ensuring Diversity in Drug Development" is now available.

The article "CSV Considerations for Client Establishment of a DCT System.

The "Overview of the FDA's "Risk-Based Credibility Assessment of AI Models" Framework" is now available.

The World of Drugs in the Language of the Next Generation

Creating the Future of Medical Care with Asia: Japan's Contribution to the Collaboration with Bac Mai Hospital (Vietnam)

Report on the JPMA Media Forum

Revision of the Transparency Guideline for the Relation between Corporate Activities and Medical Institutions

Open Call for Researchers Support and Grants "FY2025 Adoption Results" is now available.

Report on the Actual Situation Concerning Publication in MA" is now available.

Toward the Utilization of Structured Data for Clinical Trial Notification" is now available.

JPMA Rare Disease Day 2026 Symposium" Report Video and Report are now available.

Checklist for Voluntary Quality Tests_ver.1" is now available.

Presentation Material for Asian eCTD / Gateway System Information Symposium" is now available.

Notes on TMF Data Migration" is now available.

Q&A on Application for Authorized Users of the Next Generation Medical Infrastructure Act" is now available.

Briefing on Detailed Questionnaire Used for Adverse Reaction Surveillance (JPMA Electronic Model)" is now available.

We have updated the “FAQ Regarding Changes to the Industry Standard Manual ‘EDI Unified Data Format’ and the 8th System Upgrade of JD-NET.”

The industry's first Scope 3 guidelines were released at the "Ministry of the Environment Model Project Outcome Debriefing Session.

The English version of the report "Evolution and Advancement of Data Management in Drug Development(Executive Summary)" is now available.

The "Actual Conditions and Challenges of DB Research in MA: A Comprehensive Analysis (FY2025)" is now available.

The following pages are released: "[Interview with a Patient Organization] Small Questions Create the Future: Opening the Door to Participation and Collaboration - Support familia Yamaguchi for Intractable Diseases" (Japanese only).

Report on "The 5th Japan-Vietnam Joint Symposium" is now available.

The article "Toward the Use of Wearable Devices" is now available.

Proposal for holding the "Workshop on the Implementation of the Clinical Trials Ecosystem Industry Declaration 2025"" is now available.

Pathways from Development to Access to Innovation (IDAP)" is now available.

Information and background necessary for companies to utilize disease registries" is now available.

Survey on Communication Issues at the Time of DCT Introduction" is now available.

2025 Assembly of the Clinical Evaluation Subcommittee, Part 1: Presentation Materials" is posted.

Report on Results of Questionnaire Survey on Companies' Current Perceptions of Face-to-Face Advice Provided by the Pharmaceuticals and Medical Devices Agency (February 2026)" is posted.

The symposium "Covariate Adjustment for Improving Statistical Efficiency in Randomized Controlled Trials" is now available for viewing in advance.

The "Impact of the "Study Group on Regulation of Pharmaceutical Affairs to Enhance Drug Discovery and Ensure Stable Supplies of Drugs" related notifications as revealed through the results of a survey conducted in the pharmaceutical industry" is now available.

The "Reference: Creating a Society Where Clinical Trials are Accessible to All" has been updated.

Report on "CMC Strategy Forum Japan 2025" is now available.

Regarding “Recommendations on Intractable and Rare Diseases Based on a Survey of Healthcare Professionals’ Challenges”

The following pages are released: "Hands-on Workshop for Utilization of Medical Information Databases in PV Activities: Video Lecture by Dr. Chieko Ishiguro" (Japanese).

The Third Annual Neglected Tropical Diseases Contest is Held

Information on "Symposium on Pediatric Drug Development on March 17, 2026" is now available.

Implementation of the webinar "Toward the Formation of a Global Community to Promote Research and Development of Antimicrobial Agents" was featured on the INCATE website.

First Report on the Judging of the Senden Kaigi Award in the Junior High and High School Student Category

JPMA and AMED "Joint Press Conference" Report is now available.

JPMA Q&A on the Clinical Research Act and Enforcement Regulations of the Clinical Research Act" is now available.

QMS in PV" is now available.

Report on "ICH Singapore Meeting" is now available.

Report on "The 5th Seminar on Economic Security" is posted.

Mapping of Clinical Trial Documents in TMF Reference Model (Revised Version)" is available.

In Response to the FY2026 (Reiwa 8) Drug Pricing System Reform and Cost-Effectiveness Evaluation System Reform

The 148th Assembly of the Drug Evaluation Committee" is posted.

Asian eCTD / Gateway System Information" was added.

Report on "The 52nd GMP Case Study Workshop in 2025" is now available.

Results of Questionnaire on Information Provision Activities at the Time of Precautionary Statements Revision" is posted.

Special Session at the "12th Nikkei-FT Conference on Infectious Diseases

Joint Statement by Three Pharmaceutical Associations from Japan, the U.S., and Europe: Opinions on the FY2026 (Reiwa 8) Drug Price System Reform and Cost-Effectiveness Evaluation System Reform

The following pages are released: "A Review of the First 10 Years since the Introduction of the RMP System from the Pharmaceutical Industry's Perspective" (Japanese only)

Slides for eCTD v4 Implementation Promotion Symposium (JPMA Presentation)" is available.

DX Lecture Slides (19th Annual Assembly of the Japanese Society of Pharmacy)" is available.

Preliminary Study on Application of AI to Quality Management of Clinical Trials" is posted.

R & D Committee Member Companies' R&D Needs" has been updated.

The following pages are released: "Data Linkage Concept: Data Linkage from the Perspective of Overseas Regulations" (Japanese)

The "Guide to Conducting Post-Marketing Database Surveillance - November 2025 Edition" is now available.

The following pages are released / updated: "Evolution and Deepening of Data Management in Drug Development" (Japanese only)

Visit to Three Southeast Asian Countries to Host the "15th Asian Pharmaceutical Associations Collaboration Conference (APAC)

Report on the 44th Public Relations Seminar

RMP Presentation Slides (27th Annual Meeting of the Japanese Society for Drug Informatics)" is posted.

Regarding the Release of the Joint Statement “Clinical Trial Ecosystem Industry Declaration 2025”

Report on "BioJapan 2025" is now available.

The "Guidance for Conformity Surveillance of Reexamination etc. (Ver. 2.1, October 2025)" is posted.

"Report on the Results of the Questionnaire Survey on the Review Status of New Pharmaceuticals and New Biologics at the Pharmaceuticals and Medical Devices Agency -January 2025 Survey-" is available.

Report on Side Events Held during the United Nations Assembly" is posted.

We have updated the “FAQ Regarding Changes to the Industry Standard Manual ‘EDI Unified Data Format’ and the 8th System Upgrade of JD-NET.”

Slide "Survey of RMP Case Studies and Preparation of Case Studies" has been added.

The 15th APAC (Asia-Pacific Association of Pharmaceutical Manufacturers and Associations) Conference" is now available.

The following pages are released / "Names of companies that have adopted the common template for Explanatory and Consent Documents (ICF)" (Japanese only)

Announcement Posted Regarding the Webinar “Toward the Formation of a Global Community to Promote Antimicrobial R&D.”

The "eCTD v4 Preparation Guide Version 1.0" is now available.

A cover letter template has been created for use in the simplified review system in the Asian region.

Third Place Awarded in the “My CareerStudy Course Contest 2025.” JPMA’s video course for undergraduate students received high praise from student judges.

Q&A on Quality and Non-clinical Conformity Written Survey" is posted.

The "Impact on Drug Development after the Introduction of ICH M11" is now available.

Questionnaire Report on the Promotion of eSource Utilization of Electronic Medical Records, etc." is posted.

RMP Training Slides for MRs (revised August 2025)" is available.

Report on JPMA Media Forum "Two Major Issues in Countermeasures against Infectious Diseases: Countermeasures against Drug-Resistant Strains of Bacteria and Proper Understanding of Immunization" is now available.

DX Lecture Slides (58th Annual Meeting of the Pharmaceutical Society of Japan)" is now available.

The report of "The 15th Annual Meeting of the Regulatory Science Society of Japan" is now available.

Chairman Miyashira spoke at the BioJapan 2025 Luncheon Seminar titled “Tackling Challenges in Access to Medicines: Public-Private Collaboration.”

Chairman Miyashira spoke at the BioJapan 2025 Luncheon Seminar titled “Tackling Challenges in Access to Medicines: Public-Private Collaboration.”

Announcement Regarding the “JPMA Code of Practice: Month to Promote Understanding of the JPMA Code”

Participation in the “Kusuri Visionary Conference 2025”
Expanding the Circle of Stakeholders and Engaging in Discussions Toward Co-Creation

Clinical Trials Ecosystem Industry Declaration 2025 on Quality Challenges" is now available.

The following pages are released / "Names of companies that have adopted the common template for Explanatory and Consent Documents (ICF)" (Japanese only)

Report on "FY2025 Meeting of Code Administration Managers and Practitioners" is now available.

The "Reference: Creating a Society Where Clinical Trials are Accessible to All" has been updated.

The article "How to Use Simulation in Bayesian Trial Design" is now available.

The "Survey Report on Drugs Designated under the Pioneer Drug Designation System" is now available.

The "Companies that have already introduced the common template for the Explanatory and Consent Documents (ICF)" is now available.

Publication of the Book “JPMA Code of Practice (Revised May 2025)”

The article "Toward the Era of Co-Creation" <16> by Chairperson Tsukahara was published in Nikkan Yakugyo.

Report on "JPMA Media Forum" is now available.

ICH Q3E "Draft Guideline for Evaluation and Control of Extractables and Leachables of Pharmaceutical and Biological Products" is now available.

Scientific Discussion on FDA Review Report" was added.

We have published “Scientific and Practical Requirements for Drug Candidate Substances Sought by Companies: Regarding the Description of the Target Product Profile (TPP).”

The article by Chairperson Okumura on Nikkan Yakugyo was published in the "Toward the Era of Co-Creation" <14>.

The article by Chairperson Nakaji of the Pharmaceutical Evaluation Committee was published in Nikkan Yakugyo.

The article by Kurata, Chairperson of Biopharmaceuticals Committee, is published in Nikkan Yakugyo.

The article "Toward the Age of Co-creation" <12> by Chairperson Misawa was published in Nikkan Yakugyo.

The article by Chairperson of the Consumer Consultation Review Committee, Mr. Wakasugi, was published in Nikkan Yakugyo.

The article of Nikkan Yakugyo interview with Chairperson of Review Board of Ethical Drug Product Information Brochure, Mr. Kondo, was published in Nikkan Yakugyo.

The article by Chairperson Kawashima on Nikkan Yakugyo was published in the "Toward the Era of Co-Creation" <8>.

Chairperson Tada's article on Nikkan Yakugyo's "Toward the Age of Co-Creation" <9> was published.

The report on "The 3rd Japan-Malaysia Symposium on Pharmaceutical Regulation" is now available.

[For Elementary School Students and Their Parents] Perfect for the Fall Holiday Break! Hands-on Event at the National Museum of Science and Technology. “JPMA Kusurium Lab 2025 Fall”—a fun way to learn about medicines. A social media campaign offering free admission is currently underway.

The article by Chairperson Ouchi of the Code Compliance Promotion Committee was published in the "Nikkan Yakugyo" section of the "Toward the Age of Co-Creation" <7>.

ICH Project Chairperson Mr. Yokota was interviewed by Nikkan Yakugyo.

The article by Chairperson Arima on the Environmental Issues Study Group was published in the "Nikkan Yakugyo" (Daily Yakugyo).

The article "Toward the Era of Co-Creation" <4> by Chairperson Kashitani was published in Nikkan Yakugyo.

The "Reference: Creating a Society Where Clinical Trials are Accessible to All" has been updated.

JPMA members participate in the DIA 2025 Global Annual Meeting and communicate to the world about efforts to address drug lag and loss issues.

We have posted “Science and Technology Museum ‘JPMA Kusurium Lab 2025 Fall’ Invitation Campaign!”

The article by Chairperson Kumagai on the Optimization of Distribution was published in the "Nikkan Yakugyo" (Daily Yakugyo).

The article, "Toward the Era of Co-Creation <1>," by Chairperson Iwashita of the Industrial Policy Committee, was published.

We have published “Understanding the Pharmaceutical Industry Through Manga: ‘Open Up! The World of Medicines Connecting to the Future.’”

Information on "Model Credibility Evaluation in Drug Development" is now available.

Tips for Signal Management Activities in Japan" is now available.

Survey Results on Preparation and Sharing of Clinical Trial Results" is available.

We have updated the “Disclosed Information for FY 2024 Payments” in the “Transparency Guideline for Relationships Between Corporate Activities and Patient Organizations.”

We have updated the “Disclosed Information for Fiscal Year 2024 Payments” under the “Transparency Guideline for the Relation between Corporate Activities and Medical Institutions, etc.”

Reporting Form for Pharmacovigilance Regulation Survey" is now available.

The following pages are released / updated: "Names of companies that have implemented the Common Template for Explanatory and Consent Documents (ICF)" (Japanese only)

DX Presentation Slides (16th Annual Meeting of the Japanese Association of Pharmaceutical Medicine)" is now available.

Report on "The 6th Japan-Korea Symposium on Pharmaceutical Regulation" is available.

Lecture "Clinical Trial 119" is now available.

JPMA Sponsors the Sendenkaigi Award (Junior High and High School Student Division) — Creating a Future for Life Together with the Young Generation Who Will Shape Tomorrow —

Workshop "Smooth Electronic Data Submission and Effective Utilization of CDISC-compliant Data": Report on the Results of Questionnaire on "Inquiries on Electronic Data Submission" and "Handling of Deviation Information and Case Acceptance/Rejection"" is now available.

The following pages are released / updated: "Names of companies that have implemented the Common Template for Explanatory and Consent Documents (ICF)" (Japanese only)

Orientation of the Proposals for the SendenKaigi Award for Junior and Senior High School Students" is now available.

Research report on the drug-resistant bacteria issue was compiled.

Drug Resistance (AMR) Issues at the Forefront - Two doctors involved in cancer treatment talk about the current situation and challenges -" is now available.

Newly added "Examples of Utilization of RMP/RMP Materials - Mainly for Dispensing Pharmacies" is now available.

ICH M4Q(R2) "Guideline Workshops on CTD-Quality Documentation Procedure (Draft)" is now available.

Selected for the Ministry of the Environment’s “Model Project to Promote Decarbonization Across the Entire Value Chain” — 12 Companies Participate to Develop Common CO2 Emissions Calculation Rules for the Pharmaceutical Industry

Guidance for Efficient Preparation of Pharmaceutical Documentation (CSR and CTD (Clinical Tables)) in Response to Environmental Changes" is now available.

JPMA requests the government to strengthen support for unapproved drugs" is now available.

Slide "Current Status and Issues of Post-Marketing Surveillance in Japan - GPSP Questionnaire Survey" (July 5, 2025, 27th Annual Meeting of the Japanese Society for Drug Information)" is posted.

DX Lecture Slides (27th Annual Meeting of the Japanese Society for Drug Information)" is available.

ICH E21 "Inclusion of Pregnant and Lactating Women in Clinical Trials (Draft)" Information Session" is now available.

The following pages are released / updated: "Drug Use Surveillance for Patients Awareness Leaflet" (Japanese)

RMP Follow-up Survey (1st Interim Results)" is available.

Guidance for Reporting of Drug Failure for Drug Combination Products (2025 Edition)" is updated.

English version of "Non-clinical Checklist and Q&A" is now available.

Evaluation of Validation Necessary to Use Digital Biomarkers as Primary Endpoints in Clinical Trials" is now available.

The following pages are released / updated: "Names of companies that have implemented the Common Template for Explanatory and Consent Documents (ICF)" (Japanese only)

Meeting with Pharmaceuticals and Medical Devices Agency (PMDA), National Cancer Center (NCC), and National Institute of Health Risk Management (JIHS)" was held to improve the clinical trial environment in Asia.

Covariate Adjustment in Randomized Controlled Trials Based on FDA Guidance" is now available.

WHA78 Side Event in Geneva "Strengthening Strategic Partnerships to Combat Infectious Diseases (Vector-Borne Diseases, Neglected Tropical Diseases, and Emerging Infectious Diseases)" is now available.

The report of "ICH Madrid Meeting" is available.

The 51st ICH Public Meeting" is now available.

Report on the 14th APAC (Asian Pharmaceutical Association Conference)

Dawn of the ICH E6(R3) Era: The Future of Clinical Data Manager" is now available.

Information on "Patient Experience Information Useful for Decision-Making in Drug Development" (June 13, 2025) is now available.

Workshop on "R" on April 2, 2025" is now available.

Report on "FY2025 Joint Assembly of Drug Evaluation Committee and Regulatory Affairs Committee" is now available.

A "Guide for Medical Writers to Prepare Regulatory Documentation in Response to Changes in the Digital Technology Environment, including Generation AI" is now available.

Comparison of Guidance on the Use of RWD/RWE in Japan and the U.S." is now available.

The following pages are released / updated: "Names of companies that have implemented the Common Template for Explanatory and Consent Documents (ICF)" (Japanese only)

Updated "Standard Operating Procedures for Electromagnetic Handling of Clinical Trial Documents (2024 Edition)".

Guideline Workshops on ICH Q1 "Draft Guideline for Stability Testing of Drug Substances and Drug Products" (Step 2 document)" is now available.

Chairman Kinoshita spoke at a panel organized by the U.S.-based “Endpoints News.”

The "Issues and Priorities Roundtable Report on RWD/RWE Utilization" has been updated.

Regarding the Revision of the JPMA Code of Practice

The "Digital Therapeutics in Japan (DTx): Current Status and Challenges" is now available.

The following pages are released / updated: "Names of companies that have implemented the Common Template for Explanatory and Consent Documents (ICF)" (Japanese only)

The following pages are released / updated: "Reference: Creating a society where clinical trials are accessible to all.

Reference Manual for Clinical Development of Regenerative Medicine Products" is now available.

Q&A on ICF Common Template" is now available.

Handbook on Regulatory Requirements and Issuances of Electronic Information, 5th Edition" is now available.

The article "Utilization of Patient Experience Information for Patient-Focused Drug Development - For Decision-Making Based on Patients' Opinions" is now available.

The following pages are released / updated: "Names of companies that have implemented the Common Template for Explanatory and Consent Documents (ICF)" (Japanese only)

Report on "FY2024 Workshop for Product Information Overview Managers and Practitioners" is now available.

Following the “14th Asia Pharmaceutical Associations Cooperation Conference (APAC)”

“Materials from the Press Conference on the 14th Asia Pharmaceutical Association Cooperation Conference (APAC), Held on April 23” have been posted.

Video content "Messages from seniors to pharmacy students who aspire to become pharmacists" is now available.

The following pages are released / updated: "Names of companies that have implemented the Common Template for Explanatory and Consent Documents (ICF)" (Japanese only)

The video "Model Credibility Assessment in Drug Development" is now available.

Report on "JPMA Media Forum" is now available.

Report on "FY2024 Meeting of Compliance Managers and Practitioners" is now available.

The following pages are released / updated: "Names of companies that have implemented the Common Template for Explanatory and Consent Documents (ICF)" (Japanese only)

Patient Reported Outcomes in Clinical Trials: A Guide to Using PROs for Clinical Development Professionals" has been re-published.

The "Future Drug Researchers are Born! The JPMA's "Kusurium Laboratory," a popular hands-on event, was held.

Public Call for Researchers Support and Grants "FY2024 Adoption Result" is now available.

Event for medical institutions "Symposium for Promotion of ICF Common Template Utilization: Case Studies of Introduction at Medical Institutions" (Web-based event: Feb. 26, 2025) is now available.

Notice of Revision of the Common Template Document for Explanatory and Consent Documents (ICF)" is now available.

The report "Analysis of Application Documents for Regenerative Medicine Product Approval (Life Cycle Management Information)" is updated.

We have published the “Business Policy, Business Plan, and Implementation Plan” for Fiscal Year 2025.

Results of questionnaire for domestic implementation of ICH M11 "Electronically Structured and Harmonized Clinical Study Protocol (CeSHarP)" (FY2024) are now available.

#AlwaysInnovating: Pharmaceutical Industry Facts & Figures is now available.

Report on "2025 Life Science Intellectual Property Forum" is now available.

The "FY2024 Assembly of the Clinical Evaluation Subcommittee Part 2: Presentation Materials" is posted.

ICH M13B "Bioequivalence of Immediate Release Oral Solid Dosage Forms - Additional Content Biowaiver" Guideline Workshops" is posted.

ICH M15 "Draft General Principles for Model-Informed Drug Development" Information Meeting" is now available.

Briefing on "Alliance for Research in Southeast and East Asia (ARISE)" on April 2, 2025.

The "Guide to the Preparation of Periodic Reporting of Infectious Diseases (2025 Revised Edition)" is now available.

Report on "CMC Strategy Forum Japan 2024" is now available.

Presentation materials for "Symposium on eCTD v4 Implementation Promotion" held in November 2024 are now available.

How to proceed with the study of post-marketing database survey using a registry" is now available.

The following pages are released / updated: "Names of companies that have implemented the Common Template for Explanatory and Consent Documents (ICF)" (Japanese only)

The "Asian Trial Network for Adolescent and Translational Oncology Study (ATLAS project) Information Meeting" held on February 25, 2025 is now available.

The Second Neglected Tropical Diseases Contest" is now available.

Information on the value of various pharmaceutical products" is now available.

We have updated the “Transparency Guideline for the Relation between Corporate Activities and Medical Institutions”

JPMA Rare Disease Day 2025 Symposium Report" is now available.

We have posted a report on our participation in the “16th Annual Conference of the Society for Regulatory Science.”

We have posted the “Results of a Survey of Member Companies of the Drug Evaluation Committee Regarding the Use of the ICF Common Template.”

"Introduction to Patient Preference Research" has been posted.

Three Pharmaceutical Associations from Japan, the U.S., and Europe
Joint Statement on the Proposal to Expand the Cost-Effectiveness Evaluation System

Public and Private Sectors Jointly Highlight the Evolution of the Japanese Market and Clinical Trial Environment at “BIO International Convention 2026”

Regarding the JPMA’s 4th (FY2026) “Call for Proposals for Researcher Support and Grants”

We have posted a report on our participation in the “ICH Rio de Janeiro Meeting.”

We have posted a report on the “FY 2026 (53rd) GMP Roundtable.”

We have posted the “Q&A, 5th Edition, Regarding ‘Registration of Clinical Trial Status, etc.’ (Pharmaceutical and Medical Devices Safety and Evaluation Division Notice No. 0831-9, August 31, Reiwa 2).”

We have published an article titled “The Revised Next-Generation Medical Infrastructure Act and Post-Marketing Drug Safety Surveillance: Required Actions for Pharmaceutical Companies.”

Following the Cabinet’s Approval of the “Basic Policy 2026”

We have posted an article titled “JPMA’s Perspective on the FDA Roadmap and Related Matters.”

"The Potential for Bioequivalence Evaluation Using Physiological Drug Absorption Models: The Current Status and Future Prospects of Virtual BE" has been published.

—Making Drug Discovery and Biotechnology Engines of Japan’s Growth— Following the Publication of the “Working Group Roadmap by the Japan Growth Strategy Council”

We have posted the “Guide to Creating Terms of Use for the Adverse Reaction Database (DB) Tool.”

Report on the JPMA Media Forum: “The Diverse Value Brought by Innovative Medicines—Using Pediatric Acute Lymphoblastic Leukemia (ALL) as a Case Study”

We have posted the "Survey Report on the Current Status of Application Lags in Japan (March 2026)."

Theory and Practice of Model-based Meta Analysis in Drug Development" is now available.

Top Leaders of Global Biopharmaceutical Companies Meet with Prime Minister Sanae Takaichi

Workshop on April 16, 2026 "What is a Lay Summary that Responds to "I Want to Know"? ~Think Together from the Perspectives of Patients, Regulations, and Practice! ～is now available.

The 149th Assembly of the Drug Evaluation Committee" is now available.

Presentation materials and video of the symposium "Covariate Adjustment to Improve Statistical Efficiency in Randomized Controlled Trials" are now available

Results of Survey on Clinical Trials Not Relying on Visits to Medical Institutions" is now available.

Digital Applications in Preventive Medicine and Initiatives by Pharmaceutical Companies" is now available.

Explanation Video to Promote Understanding of ICH-E6 (R3)" is now available.

Survey and Discussion on Data Utilization for jRCT and Clinical Trial Notification for ICH M11 Implementation" is now available.

Industry Workshop on the Implementation of the "Clinical Trials Ecosystem Industry Declaration 2025" is now available.

Workshop for Case Evaluation Officers" is now available.

Guidance for Preparation of the "Infectious Disease Evaluation Report" (2026 Edition)" is now available.

A Beginner's Guide to Using NDB in the Pharmaceutical Industry" is now available.

Held "2026 Life Science IP Forum

The following pages are released / "Names of companies that have adopted the common template for Explanatory and Consent Documents (ICF)" (Japanese only)

Collection of Examples of Cloud System Introduction at Medical Institutions" has been posted on the "Standard Operating Procedures, etc. for Electromagnetic Handling of Clinical Trial Documents (2024 Edition)" page.

Analysis of Application Materials for Regenerative Medicine Product Approval (Life Cycle Management Information)" is available.

Q&A on Commercial Production Digital Transformation (DX) Promotion Task Force (TF) Case Studies" is now available.

Handbook of Regulatory Requirements and Issuances for Electronic Information, Sixth Edition" is now available.

The "Contribution of Clinical Pharmacology to Ensuring Diversity in Drug Development" is now available.

The article "CSV Considerations for Client Establishment of a DCT System.

The "Overview of the FDA's "Risk-Based Credibility Assessment of AI Models" Framework" is now available.

Report on the JPMA Media Forum

Report on the Actual Situation Concerning Publication in MA" is now available.

Toward the Utilization of Structured Data for Clinical Trial Notification" is now available.

JPMA Rare Disease Day 2026 Symposium" Report Video and Report are now available.

Checklist for Voluntary Quality Tests_ver.1" is now available.

Presentation Material for Asian eCTD / Gateway System Information Symposium" is now available.

Notes on TMF Data Migration" is now available.

Q&A on Application for Authorized Users of the Next Generation Medical Infrastructure Act" is now available.

Briefing on Detailed Questionnaire Used for Adverse Reaction Surveillance (JPMA Electronic Model)" is now available.

The English version of the report "Evolution and Advancement of Data Management in Drug Development(Executive Summary)" is now available.

The "Actual Conditions and Challenges of DB Research in MA: A Comprehensive Analysis (FY2025)" is now available.

The article "Toward the Use of Wearable Devices" is now available.

Proposal for holding the "Workshop on the Implementation of the Clinical Trials Ecosystem Industry Declaration 2025"" is now available.

Information and background necessary for companies to utilize disease registries" is now available.

Survey on Communication Issues at the Time of DCT Introduction" is now available.

2025 Assembly of the Clinical Evaluation Subcommittee, Part 1: Presentation Materials" is posted.

Report on Results of Questionnaire Survey on Companies' Current Perceptions of Face-to-Face Advice Provided by the Pharmaceuticals and Medical Devices Agency (February 2026)" is posted.

The symposium "Covariate Adjustment for Improving Statistical Efficiency in Randomized Controlled Trials" is now available for viewing in advance.

The "Impact of the "Study Group on Regulation of Pharmaceutical Affairs to Enhance Drug Discovery and Ensure Stable Supplies of Drugs" related notifications as revealed through the results of a survey conducted in the pharmaceutical industry" is now available.

Report on "CMC Strategy Forum Japan 2025" is now available.

The following pages are released: "Hands-on Workshop for Utilization of Medical Information Databases in PV Activities: Video Lecture by Dr. Chieko Ishiguro" (Japanese).

The Third Annual Neglected Tropical Diseases Contest is Held

Information on "Symposium on Pediatric Drug Development on March 17, 2026" is now available.

JPMA and AMED "Joint Press Conference" Report is now available.

QMS in PV" is now available.

Report on "ICH Singapore Meeting" is now available.

Mapping of Clinical Trial Documents in TMF Reference Model (Revised Version)" is available.

The 148th Assembly of the Drug Evaluation Committee" is posted.

Asian eCTD / Gateway System Information" was added.

Report on "The 52nd GMP Case Study Workshop in 2025" is now available.

Results of Questionnaire on Information Provision Activities at the Time of Precautionary Statements Revision" is posted.

The following pages are released: "A Review of the First 10 Years since the Introduction of the RMP System from the Pharmaceutical Industry's Perspective" (Japanese only)

Slides for eCTD v4 Implementation Promotion Symposium (JPMA Presentation)" is available.

DX Lecture Slides (19th Annual Assembly of the Japanese Society of Pharmacy)" is available.

Preliminary Study on Application of AI to Quality Management of Clinical Trials" is posted.

R & D Committee Member Companies' R&D Needs" has been updated.

The following pages are released: "Data Linkage Concept: Data Linkage from the Perspective of Overseas Regulations" (Japanese)

The "Guide to Conducting Post-Marketing Database Surveillance - November 2025 Edition" is now available.

The following pages are released / updated: "Evolution and Deepening of Data Management in Drug Development" (Japanese only)

RMP Presentation Slides (27th Annual Meeting of the Japanese Society for Drug Informatics)" is posted.

Regarding the Release of the Joint Statement “Clinical Trial Ecosystem Industry Declaration 2025”

Report on "BioJapan 2025" is now available.

The "Guidance for Conformity Surveillance of Reexamination etc. (Ver. 2.1, October 2025)" is posted.

"Report on the Results of the Questionnaire Survey on the Review Status of New Pharmaceuticals and New Biologics at the Pharmaceuticals and Medical Devices Agency -January 2025 Survey-" is available.

Slide "Survey of RMP Case Studies and Preparation of Case Studies" has been added.

The following pages are released / "Names of companies that have adopted the common template for Explanatory and Consent Documents (ICF)" (Japanese only)

The "eCTD v4 Preparation Guide Version 1.0" is now available.

Q&A on Quality and Non-clinical Conformity Written Survey" is posted.

The "Impact on Drug Development after the Introduction of ICH M11" is now available.

Questionnaire Report on the Promotion of eSource Utilization of Electronic Medical Records, etc." is posted.

RMP Training Slides for MRs (revised August 2025)" is available.

DX Lecture Slides (58th Annual Meeting of the Pharmaceutical Society of Japan)" is now available.

The report of "The 15th Annual Meeting of the Regulatory Science Society of Japan" is now available.

Clinical Trials Ecosystem Industry Declaration 2025 on Quality Challenges" is now available.

The following pages are released / "Names of companies that have adopted the common template for Explanatory and Consent Documents (ICF)" (Japanese only)

The article "How to Use Simulation in Bayesian Trial Design" is now available.

The "Survey Report on Drugs Designated under the Pioneer Drug Designation System" is now available.

The "Companies that have already introduced the common template for the Explanatory and Consent Documents (ICF)" is now available.

The article "Toward the Era of Co-Creation" <16> by Chairperson Tsukahara was published in Nikkan Yakugyo.

Report on "JPMA Media Forum" is now available.

ICH Q3E "Draft Guideline for Evaluation and Control of Extractables and Leachables of Pharmaceutical and Biological Products" is now available.

Scientific Discussion on FDA Review Report" was added.

We have published “Scientific and Practical Requirements for Drug Candidate Substances Sought by Companies: Regarding the Description of the Target Product Profile (TPP).”

The article by Chairperson Okumura on Nikkan Yakugyo was published in the "Toward the Era of Co-Creation" <14>.

The article by Chairperson Nakaji of the Pharmaceutical Evaluation Committee was published in Nikkan Yakugyo.

The article by Kurata, Chairperson of Biopharmaceuticals Committee, is published in Nikkan Yakugyo.

The article by Chairperson Kawashima on Nikkan Yakugyo was published in the "Toward the Era of Co-Creation" <8>.

ICH Project Chairperson Mr. Yokota was interviewed by Nikkan Yakugyo.

The article "Toward the Era of Co-Creation" <4> by Chairperson Kashitani was published in Nikkan Yakugyo.

The article, "Toward the Era of Co-Creation <1>," by Chairperson Iwashita of the Industrial Policy Committee, was published.

Information on "Model Credibility Evaluation in Drug Development" is now available.

Tips for Signal Management Activities in Japan" is now available.

Survey Results on Preparation and Sharing of Clinical Trial Results" is available.

Reporting Form for Pharmacovigilance Regulation Survey" is now available.

The following pages are released / updated: "Names of companies that have implemented the Common Template for Explanatory and Consent Documents (ICF)" (Japanese only)

DX Presentation Slides (16th Annual Meeting of the Japanese Association of Pharmaceutical Medicine)" is now available.

Lecture "Clinical Trial 119" is now available.

Workshop "Smooth Electronic Data Submission and Effective Utilization of CDISC-compliant Data": Report on the Results of Questionnaire on "Inquiries on Electronic Data Submission" and "Handling of Deviation Information and Case Acceptance/Rejection"" is now available.

The following pages are released / updated: "Names of companies that have implemented the Common Template for Explanatory and Consent Documents (ICF)" (Japanese only)

Newly added "Examples of Utilization of RMP/RMP Materials - Mainly for Dispensing Pharmacies" is now available.

ICH M4Q(R2) "Guideline Workshops on CTD-Quality Documentation Procedure (Draft)" is now available.

Guidance for Efficient Preparation of Pharmaceutical Documentation (CSR and CTD (Clinical Tables)) in Response to Environmental Changes" is now available.

Slide "Current Status and Issues of Post-Marketing Surveillance in Japan - GPSP Questionnaire Survey" (July 5, 2025, 27th Annual Meeting of the Japanese Society for Drug Information)" is posted.

DX Lecture Slides (27th Annual Meeting of the Japanese Society for Drug Information)" is available.

ICH E21 "Inclusion of Pregnant and Lactating Women in Clinical Trials (Draft)" Information Session" is now available.

The following pages are released / updated: "Drug Use Surveillance for Patients Awareness Leaflet" (Japanese)

RMP Follow-up Survey (1st Interim Results)" is available.

Guidance for Reporting of Drug Failure for Drug Combination Products (2025 Edition)" is updated.

English version of "Non-clinical Checklist and Q&A" is now available.

Evaluation of Validation Necessary to Use Digital Biomarkers as Primary Endpoints in Clinical Trials" is now available.

The following pages are released / updated: "Names of companies that have implemented the Common Template for Explanatory and Consent Documents (ICF)" (Japanese only)

Covariate Adjustment in Randomized Controlled Trials Based on FDA Guidance" is now available.

The report of "ICH Madrid Meeting" is available.

The 51st ICH Public Meeting" is now available.

Dawn of the ICH E6(R3) Era: The Future of Clinical Data Manager" is now available.

Information on "Patient Experience Information Useful for Decision-Making in Drug Development" (June 13, 2025) is now available.

Workshop on "R" on April 2, 2025" is now available.

Report on "FY2025 Joint Assembly of Drug Evaluation Committee and Regulatory Affairs Committee" is now available.

A "Guide for Medical Writers to Prepare Regulatory Documentation in Response to Changes in the Digital Technology Environment, including Generation AI" is now available.

Comparison of Guidance on the Use of RWD/RWE in Japan and the U.S." is now available.

The following pages are released / updated: "Names of companies that have implemented the Common Template for Explanatory and Consent Documents (ICF)" (Japanese only)

Updated "Standard Operating Procedures for Electromagnetic Handling of Clinical Trial Documents (2024 Edition)".

Guideline Workshops on ICH Q1 "Draft Guideline for Stability Testing of Drug Substances and Drug Products" (Step 2 document)" is now available.

The "Issues and Priorities Roundtable Report on RWD/RWE Utilization" has been updated.

The "Digital Therapeutics in Japan (DTx): Current Status and Challenges" is now available.

The following pages are released / updated: "Names of companies that have implemented the Common Template for Explanatory and Consent Documents (ICF)" (Japanese only)

Reference Manual for Clinical Development of Regenerative Medicine Products" is now available.

Q&A on ICF Common Template" is now available.

Handbook on Regulatory Requirements and Issuances of Electronic Information, 5th Edition" is now available.

The article "Utilization of Patient Experience Information for Patient-Focused Drug Development - For Decision-Making Based on Patients' Opinions" is now available.

The following pages are released / updated: "Names of companies that have implemented the Common Template for Explanatory and Consent Documents (ICF)" (Japanese only)

The following pages are released / updated: "Names of companies that have implemented the Common Template for Explanatory and Consent Documents (ICF)" (Japanese only)

The video "Model Credibility Assessment in Drug Development" is now available.

The following pages are released / updated: "Names of companies that have implemented the Common Template for Explanatory and Consent Documents (ICF)" (Japanese only)

Patient Reported Outcomes in Clinical Trials: A Guide to Using PROs for Clinical Development Professionals" has been re-published.

Event for medical institutions "Symposium for Promotion of ICF Common Template Utilization: Case Studies of Introduction at Medical Institutions" (Web-based event: Feb. 26, 2025) is now available.

Notice of Revision of the Common Template Document for Explanatory and Consent Documents (ICF)" is now available.

The report "Analysis of Application Documents for Regenerative Medicine Product Approval (Life Cycle Management Information)" is updated.

Results of questionnaire for domestic implementation of ICH M11 "Electronically Structured and Harmonized Clinical Study Protocol (CeSHarP)" (FY2024) are now available.

Report on "2025 Life Science Intellectual Property Forum" is now available.

The "FY2024 Assembly of the Clinical Evaluation Subcommittee Part 2: Presentation Materials" is posted.

ICH M13B "Bioequivalence of Immediate Release Oral Solid Dosage Forms - Additional Content Biowaiver" Guideline Workshops" is posted.

ICH M15 "Draft General Principles for Model-Informed Drug Development" Information Meeting" is now available.

Briefing on "Alliance for Research in Southeast and East Asia (ARISE)" on April 2, 2025.

The "Guide to the Preparation of Periodic Reporting of Infectious Diseases (2025 Revised Edition)" is now available.

Report on "CMC Strategy Forum Japan 2024" is now available.

Presentation materials for "Symposium on eCTD v4 Implementation Promotion" held in November 2024 are now available.

How to proceed with the study of post-marketing database survey using a registry" is now available.

The following pages are released / updated: "Names of companies that have implemented the Common Template for Explanatory and Consent Documents (ICF)" (Japanese only)

The "Asian Trial Network for Adolescent and Translational Oncology Study (ATLAS project) Information Meeting" held on February 25, 2025 is now available.

JPMA Rare Disease Day 2025 Symposium Report" is now available.

“Medication Consultation Desk (for Healthcare Professionals)” has been posted.

Information on the “Symposium on Pediatric Drug Development: ‘Envisioning the Future of Pediatric Drug Development—Challenges in the New Era Brought About by the Revision of the Pharmaceutical and Medical Devices Act,’ to be Held on March 17, 2026” has been posted.

We have posted an article titled “Side Event Report — 79th World Health Assembly (WHA79)”

Results of Questionnaire on Patient Public Involvement (PPI/E) Activity Initiatives (conducted February-March 2025)" is now available.

Explanation of "Handling of Provision of Information for Clinical Trials, etc." and Q&A.

Survey and Discussion on Data Utilization for jRCT and Clinical Trial Notification for ICH M11 Implementation" is now available.

Workshop for Case Evaluation Officers" is now available.

Positioning Map Analysis of Patients' Web-based Drug Information Search" is now available.

Following the “15th Asia Pharmaceutical Association Cooperation Conference (APAC)”

Materials from the “15th Asia Pharmaceutical Associations Conference (APAC) Press Conference”

Creating the Future of Medical Care with Asia: Japan's Contribution to the Collaboration with Bac Mai Hospital (Vietnam)

JPMA Rare Disease Day 2026 Symposium" Report Video and Report are now available.

We have updated the “FAQ Regarding Changes to the Industry Standard Manual ‘EDI Unified Data Format’ and the 8th System Upgrade of JD-NET.”

Report on "The 5th Japan-Vietnam Joint Symposium" is now available.

Pathways from Development to Access to Innovation (IDAP)" is now available.

The "Reference: Creating a Society Where Clinical Trials are Accessible to All" has been updated.

Report on "The 5th Seminar on Economic Security" is posted.

In Response to the FY2026 (Reiwa 8) Drug Pricing System Reform and Cost-Effectiveness Evaluation System Reform

Special Session at the "12th Nikkei-FT Conference on Infectious Diseases

Joint Statement by Three Pharmaceutical Associations from Japan, the U.S., and Europe: Opinions on the FY2026 (Reiwa 8) Drug Price System Reform and Cost-Effectiveness Evaluation System Reform

Visit to Three Southeast Asian Countries to Host the "15th Asian Pharmaceutical Associations Collaboration Conference (APAC)

We have updated the “FAQ Regarding Changes to the Industry Standard Manual ‘EDI Unified Data Format’ and the 8th System Upgrade of JD-NET.”

The 15th APAC (Asia-Pacific Association of Pharmaceutical Manufacturers and Associations) Conference" is now available.

Announcement Posted Regarding the Webinar “Toward the Formation of a Global Community to Promote Antimicrobial R&D.”

A cover letter template has been created for use in the simplified review system in the Asian region.

Report on JPMA Media Forum "Two Major Issues in Countermeasures against Infectious Diseases: Countermeasures against Drug-Resistant Strains of Bacteria and Proper Understanding of Immunization" is now available.

Chairman Miyashira spoke at the BioJapan 2025 Luncheon Seminar titled “Tackling Challenges in Access to Medicines: Public-Private Collaboration.”

Chairman Miyashira spoke at the BioJapan 2025 Luncheon Seminar titled “Tackling Challenges in Access to Medicines: Public-Private Collaboration.”

The report on "The 3rd Japan-Malaysia Symposium on Pharmaceutical Regulation" is now available.

JPMA members participate in the DIA 2025 Global Annual Meeting and communicate to the world about efforts to address drug lag and loss issues.

The article by Chairperson Kumagai on the Optimization of Distribution was published in the "Nikkan Yakugyo" (Daily Yakugyo).

The article, "Toward the Era of Co-Creation <1>," by Chairperson Iwashita of the Industrial Policy Committee, was published.

Report on "The 6th Japan-Korea Symposium on Pharmaceutical Regulation" is available.

Research report on the drug-resistant bacteria issue was compiled.

Drug Resistance (AMR) Issues at the Forefront - Two doctors involved in cancer treatment talk about the current situation and challenges -" is now available.

JPMA requests the government to strengthen support for unapproved drugs" is now available.

Meeting with Pharmaceuticals and Medical Devices Agency (PMDA), National Cancer Center (NCC), and National Institute of Health Risk Management (JIHS)" was held to improve the clinical trial environment in Asia.

Report on the 14th APAC (Asian Pharmaceutical Association Conference)

Chairman Kinoshita spoke at a panel organized by the U.S.-based “Endpoints News.”

Following the “14th Asia Pharmaceutical Associations Cooperation Conference (APAC)”

“Materials from the Press Conference on the 14th Asia Pharmaceutical Association Cooperation Conference (APAC), Held on April 23” have been posted.

Report on "JPMA Media Forum" is now available.

Information on the value of various pharmaceutical products" is now available.

JPMA Rare Disease Day 2025 Symposium Report" is now available.

We held the “FY 2026 Meeting of Compliance Management Officers and Practitioners.”

Videos related to the JPMA Code Awareness Month have been posted.

The “FY2026 Guidelines for the Open Call for Researcher Support and Grants” have been published.

We have posted the “Publicly Disclosed Information for FY 2025 Payments” from the “Transparency Guideline for Relationships Between Corporate Activities and Patient Organizations.”

We have posted the “Disclosed Information for Fiscal Year 2025 Payments” under the “Transparency Guideline for the Relation between Corporate Activities and Medical Institutions, etc.”

We have posted the report titled “The 19th Survey on Consumer Attitudes Toward Medicines and the Pharmaceutical Industry.”

We have published the “JPMA Newsletter, July 2026 Issue No. 230.”

We have posted “On Institutional Measures to Ensure a Stable Supply of Medicines and Other Products Necessary for Infectious Disease Control and to Promote Antimicrobial Drug Discovery.”

Information on the “Symposium on Pediatric Drug Development: ‘Envisioning the Future of Pediatric Drug Development—Challenges in the New Era Brought About by the Revision of the Pharmaceutical and Medical Devices Act,’ to be Held on March 17, 2026” has been posted.

Five JPMA Member Companies Participate in “Girls Meet STEM” — Each Company Hosts Its Own Program —

We have posted the “Guide to Creating Terms of Use for the Adverse Reaction Database (DB) Tool.”

Report on Participation in “Medicine Festival 2026—A Science Experience Event for Children and Adults Alike”

Results of Questionnaire on Patient Public Involvement (PPI/E) Activity Initiatives (conducted February-March 2025)" is now available.

Interview with a Patient Organization: "I wish I had a PAH Association! is changing the future" is now available.

Report on "The 45th Public Relations Seminar" is now available.

We have published the “JPMA Newsletter, May 2026 Issue No. 229.”

Communication of Drug Information to Create Satisfaction" is now available.

The "FY2025 Meeting of Compliance Management Managers and Practitioners" was held.

Girls Meet STEM to Experience "The Moment Drugs are Created"-Girls in Junior High and High School Take on the World of Drug Discovery-.

JPMA Newsletter [Extra]: JPMA Holds First Town Hall Meeting! is now available.

Workshop for Persons Responsible for Product Information Overview Management and Practical Responsibility for Product Information Overview Management in 2025" was held.

Interviews with Patients' Organizations] Patients' Associations are Jewel Boxes! Let's put our thoughts into words! Osaka IBD" is now available.

“Don’t Blindly Believe Medical and Health Information!” Three Organizations Produce and Release Public Awareness Materials for the General Public

The World of Drugs in the Language of the Next Generation

Revision of the Transparency Guideline for the Relation between Corporate Activities and Medical Institutions

Open Call for Researchers Support and Grants "FY2025 Adoption Results" is now available.

JPMA Rare Disease Day 2026 Symposium" Report Video and Report are now available.

The industry's first Scope 3 guidelines were released at the "Ministry of the Environment Model Project Outcome Debriefing Session.

The following pages are released: "[Interview with a Patient Organization] Small Questions Create the Future: Opening the Door to Participation and Collaboration - Support familia Yamaguchi for Intractable Diseases" (Japanese only).

Regarding “Recommendations on Intractable and Rare Diseases Based on a Survey of Healthcare Professionals’ Challenges”

Implementation of the webinar "Toward the Formation of a Global Community to Promote Research and Development of Antimicrobial Agents" was featured on the INCATE website.

First Report on the Judging of the Senden Kaigi Award in the Junior High and High School Student Category

JPMA Q&A on the Clinical Research Act and Enforcement Regulations of the Clinical Research Act" is now available.

Report on the 44th Public Relations Seminar

Report on Side Events Held during the United Nations Assembly" is posted.

Third Place Awarded in the “My CareerStudy Course Contest 2025.” JPMA’s video course for undergraduate students received high praise from student judges.

Announcement Regarding the “JPMA Code of Practice: Month to Promote Understanding of the JPMA Code”

Participation in the “Kusuri Visionary Conference 2025”
Expanding the Circle of Stakeholders and Engaging in Discussions Toward Co-Creation

Report on "FY2025 Meeting of Code Administration Managers and Practitioners" is now available.

The "Reference: Creating a Society Where Clinical Trials are Accessible to All" has been updated.

Publication of the Book “JPMA Code of Practice (Revised May 2025)”

The article "Toward the Age of Co-creation" <12> by Chairperson Misawa was published in Nikkan Yakugyo.

The article by Chairperson of the Consumer Consultation Review Committee, Mr. Wakasugi, was published in Nikkan Yakugyo.

The article of Nikkan Yakugyo interview with Chairperson of Review Board of Ethical Drug Product Information Brochure, Mr. Kondo, was published in Nikkan Yakugyo.

Chairperson Tada's article on Nikkan Yakugyo's "Toward the Age of Co-Creation" <9> was published.

[For Elementary School Students and Their Parents] Perfect for the Fall Holiday Break! Hands-on Event at the National Museum of Science and Technology. “JPMA Kusurium Lab 2025 Fall”—a fun way to learn about medicines. A social media campaign offering free admission is currently underway.

The article by Chairperson Ouchi of the Code Compliance Promotion Committee was published in the "Nikkan Yakugyo" section of the "Toward the Age of Co-Creation" <7>.

The article by Chairperson Arima on the Environmental Issues Study Group was published in the "Nikkan Yakugyo" (Daily Yakugyo).

The "Reference: Creating a Society Where Clinical Trials are Accessible to All" has been updated.

We have posted “Science and Technology Museum ‘JPMA Kusurium Lab 2025 Fall’ Invitation Campaign!”

We have published “Understanding the Pharmaceutical Industry Through Manga: ‘Open Up! The World of Medicines Connecting to the Future.’”

We have updated the “Disclosed Information for FY 2024 Payments” in the “Transparency Guideline for Relationships Between Corporate Activities and Patient Organizations.”

We have updated the “Disclosed Information for Fiscal Year 2024 Payments” under the “Transparency Guideline for the Relation between Corporate Activities and Medical Institutions, etc.”

JPMA Sponsors the Sendenkaigi Award (Junior High and High School Student Division) — Creating a Future for Life Together with the Young Generation Who Will Shape Tomorrow —

Orientation of the Proposals for the SendenKaigi Award for Junior and Senior High School Students" is now available.

Selected for the Ministry of the Environment’s “Model Project to Promote Decarbonization Across the Entire Value Chain” — 12 Companies Participate to Develop Common CO2 Emissions Calculation Rules for the Pharmaceutical Industry

WHA78 Side Event in Geneva "Strengthening Strategic Partnerships to Combat Infectious Diseases (Vector-Borne Diseases, Neglected Tropical Diseases, and Emerging Infectious Diseases)" is now available.

Regarding the Revision of the JPMA Code of Practice

The following pages are released / updated: "Reference: Creating a society where clinical trials are accessible to all.

Report on "FY2024 Workshop for Product Information Overview Managers and Practitioners" is now available.

Video content "Messages from seniors to pharmacy students who aspire to become pharmacists" is now available.

Report on "JPMA Media Forum" is now available.

Report on "FY2024 Meeting of Compliance Managers and Practitioners" is now available.

The "Future Drug Researchers are Born! The JPMA's "Kusurium Laboratory," a popular hands-on event, was held.

Public Call for Researchers Support and Grants "FY2024 Adoption Result" is now available.

We have published the “Business Policy, Business Plan, and Implementation Plan” for Fiscal Year 2025.

#AlwaysInnovating: Pharmaceutical Industry Facts & Figures is now available.

The Second Neglected Tropical Diseases Contest" is now available.

We have updated the “Transparency Guideline for the Relation between Corporate Activities and Medical Institutions”

JPMA Rare Disease Day 2025 Symposium Report" is now available.